

# Stereoselective synthesis of chiral, non-racemic 1,2,3-tri- and 1,3-disubstituted ferrocene derivatives

Marianne Steurer, Karin Tiedl, Yaping Wang and Walter Weissensteiner\*

Received (in Cambridge, UK) 22nd June 2005, Accepted 9th August 2005


First published as an Advance Article on the web 7th September 2005

DOI: 10.1039/b508761a

Chiral, non-racemic 1,2,3-trisubstituted ferrocene derivatives are accessible from monosubstituted ferrocenes through two sequential *ortho*-deprotonation reactions; removal of the central substituent gives 1,3-disubstituted ferrocenes.

Chiral non-racemic ferrocene derivatives have found broad application as ligands for homogeneous enantioselective catalysts.<sup>1</sup> In this respect, 1,2-disubstituted ferrocenes are mainly used but 1,1',2-tri- or 1,1',2,2'-tetrasubstituted ferrocenes are also employed. In general, ferrocenes with such substitution patterns are usually prepared from mono- or 1,1'-disubstituted precursors by stereoselective *ortho*-metallation reactions.<sup>2</sup> Interestingly, applications of chiral non-racemic 1,3-disubstituted ferrocenes are very rare and this might be due to the fact that suitable methods for the synthesis of such derivatives are lacking.<sup>3</sup> Only recently, in the context of ferrocene-based pincer ligands,<sup>4</sup> Brown and co-workers reported a broadly applicable method for the synthesis of achiral or racemic 1,3-disubstituted ferrocene derivatives, with the key step of this reaction sequence being a selective *meta*-lithiation of ferrocenyl-tolyl sulfide.<sup>5</sup> Attempts to carry out this reaction in an enantioselective manner have not yet been successful and, in addition, methods for separating the enantiomers of racemic mixtures are very limited.<sup>5,6</sup> For these reasons we became interested in the development of general and preparatively useful methods for the synthesis of chiral, non-racemic 1,3-disubstituted ferrocenes.

In our search for suitable methods, we investigated the reaction sequence depicted in Scheme 1: starting from a suitable monosubstituted ferrocene derivative (Fc-R<sup>1</sup>), 1,2,3-trisubstituted intermediates are built up in two steps, both of which involve *ortho*-deprotonation reactions. Subsequent removal of the central substituent (R<sup>c</sup>) gives 1,3-disubstituted ferrocenes. R<sup>1</sup> can be chosen from a broad selection of *ortho*-directing groups<sup>1,2</sup> but the central substituent R<sup>c</sup> must be both *ortho*-directing and removable. Possible candidates for R<sup>c</sup> are the halides (chloride<sup>7</sup> and bromide<sup>8</sup>) as well as sulfinyl and sulfonyl groups.<sup>9</sup> In our opinion bromide was best suited for this purpose and it was




**Scheme 1** General reaction scheme for the synthesis of 1,2,3-tri- and 1,3-disubstituted ferrocenes.

Universität Wien, Fakultät für Chemie, Währinger Straße 38, Wien, A-1090, Austria. E-mail: walter.weissensteiner@univie.ac.at


therefore tested in three reaction sequences in combination with substituents (R<sup>1</sup>) 1-dimethylaminoethyl [CH(NMe<sub>2</sub>)Me], the ephedrine derivative CH<sub>2</sub>N(Me)CH(Me)CH(Ph)OMe and the *p*-tolylsulfinyl [4-CH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>S(O)] unit.

In the first reaction sequence [R<sup>1</sup> = CH(NMe<sub>2</sub>)Me and R<sup>c</sup> = Br (Scheme 2)] commercially available (*R*)-*N,N*-(1-dimethylaminoethyl)ferrocene [Ugi's amine, (*R*)-**1**] was reacted using a literature procedure<sup>10</sup> with *s*-BuLi and F<sub>2</sub>BrCCBrF<sub>2</sub> to give (*R*,*S*<sub>p</sub>)-**2** in 88% yield. In order to optimise the subsequent deprotonation step with respect to temperature and the amount of base, different conditions were applied to the reaction of (*R*,*S*<sub>p</sub>)-**2** with Li-TMP (TMP = 2,2,6,6-tetramethyl piperidine) as the base and ClSiMe<sub>3</sub> as the electrophile.

The use of these optimised conditions† and dimethylformamide as the electrophile gave aldehyde (*R*,*R*<sub>p</sub>)-**3** exclusively (82%). Reduction of this compound with LiAlH<sub>4</sub> gave alcohol (*R*,*R*<sub>p</sub>)-**4** in 90% yield and subsequent reaction with 2.5 equivalents of *n*-BuLi and H<sub>2</sub>O resulted in the 1,3-disubstituted ferrocenyl aminoalcohol (*R*,*S*<sub>p</sub>)-**5** (88%). It is clear that a variety of analogous derivatives of



**Scheme 2** Synthesis of 1,3-disubstituted ferrocenes; reaction sequence 1. (a) *s*-BuLi, Et<sub>2</sub>O, 0 °C, 4 h; -78 °C, F<sub>2</sub>BrCCBrF<sub>2</sub>, THF, rt, 17 h, 88%; (b) Li-TMP, THF, -78 °C 30 min, -30 °C 3 h; DMF, 0 °C 16 h, 82%; (c) 0 °C, LiAlH<sub>4</sub>, THF, rt, 16 h, 90%; (d) -78 °C, *n*-BuLi, 0 °C 30 min, H<sub>2</sub>O, 88%; (e) HPPH<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub>, HBF<sub>4</sub>, rt 16 h, 67%; (f) BH<sub>3</sub>·THF, rt 16 h, 85%. TMP = 2,2,6,6-tetramethylpiperidine, DMF = *N,N*-dimethylformamide. Overall yield **1** → **5**: 57%.




**Scheme 3** Synthesis of 1,3-disubstituted ferrocenes; reaction sequence 2. (a) *t*-BuLi, pentane,  $-78\text{ }^{\circ}\text{C}$  1.5 h,  $-30\text{ }^{\circ}\text{C}$  2.5 h;  $\text{F}_2\text{BrCCBrF}_2$ , THF,  $-78\text{ }^{\circ}\text{C}$  30 min, rt 16 h, 87%; (b)  $\text{Ac}_2\text{O}$ ,  $150\text{ }^{\circ}\text{C}$  3 h, 79%; (c)  $\text{K}_2\text{CO}_3$ , MeOH,  $45\text{ }^{\circ}\text{C}$  3.5 h, 96%; (d)  $0\text{ }^{\circ}\text{C}$ , *t*-Bu(Me) $_2$ SiCl, imidazole, DMF, rt 17 h, 99%; (e) Li-TMP, THF,  $-78\text{ }^{\circ}\text{C}$  30 min,  $-30\text{ }^{\circ}\text{C}$  3 h; DMF,  $0\text{ }^{\circ}\text{C}$  1 h, 79%; (f)  $0\text{ }^{\circ}\text{C}$ ,  $\text{LiAlH}_4$ , THF, rt 16 h, 82%; (g)  $-78\text{ }^{\circ}\text{C}$ , *n*-BuLi,  $0\text{ }^{\circ}\text{C}$  30 min,  $\text{H}_2\text{O}$ , 90%. TBDSM = *t*-butyldimethylsilyl. Overall yield **8**  $\rightarrow$  **15**: 38 %.

**3**, **4** and **5** can be accessed by either using different electrophiles in the *ortho*-deprotonation step of **2** or by functional group transformation of **4** and **5** or their analogues. As an example, we synthesised a potential pincer ligand,<sup>4</sup> the aminophosphine (*R,S<sub>p</sub>*)-**6** (67%),<sup>11</sup> as well as its bisborane complex (*R,S<sub>p</sub>*)-**7** (85%).

The second reaction sequence [ $\text{R}^1 = \text{CH}_2\text{N}(\text{Me})\text{CH}(\text{Me})\text{CH}(\text{Ph})\text{OMe}$  and  $\text{R}^c = \text{Br}$  (Scheme 3)] starts from an *O*-methylephedrine-substituted ferrocene derivative and allows the synthesis of exclusively planar chiral, non-racemic 1,3-disubstituted ferrocenes. Monosubstituted ferrocene derivative (*1R,2S*)-**8**, which is easily accessible from *N*-ferrocenylmethyl-*N,N,N*-trimethylammonium iodide and *O*-methylephedrine,<sup>12</sup> was reacted with *t*-BuLi and  $\text{F}_2\text{BrCCBrF}_2$  to give (*1R,2S,R<sub>p</sub>*)-**9** in 87% yield and 98% d.e. All attempts to selectively *ortho*-deprotonate bromide **9** led to product mixtures and, in an effort to overcome this problem, the *O*-methylephedrine unit was replaced by a *tert*-butyldimethylsilyl-protected hydroxyl group (Scheme 3, **9**  $\rightarrow$  **12**, 75%).<sup>13</sup> In this case, the use of the reaction conditions optimised for **2** enabled the selective transformation of bromide (*R<sub>p</sub>*)-**12** into aldehyde (*S<sub>p</sub>*)-**13** (79%) which, after reduction with  $\text{LiAlH}_4$ , gave alcohol (*R<sub>p</sub>*)-**14** (82%). Finally, reaction with *n*-BuLi and  $\text{H}_2\text{O}$  removed the bromide and gave the 1,3-disubstituted ferrocene derivative (*S<sub>p</sub>*)-**15** in 90% yield. In this case it is also expected that derivatives **14** and **15** (like **4** and **5**) can serve as enantiopure starting materials for a number of related products—including pincer ligands.

In the third reaction sequence the use of bromide as the central substituent was combined with the *ortho*-directing *p*-tolylsulfinyl substituent [ $\text{R}^1 = 4\text{-CH}_3\text{C}_6\text{H}_4\text{S}(\text{O})$  and  $\text{R}^c = \text{Br}$  (Scheme 4)]. Bromide (*R,S<sub>p</sub>*)-**17** was prepared by reacting *p*-tolyl-ferrocenyl sulfoxide<sup>14</sup> (*R*)-**16** with LDA and  $\text{F}_2\text{BrCCBrF}_2$  (85%)<sup>15</sup> and the product was subsequently reduced with sodium iodide and chlorotrimethylsilane to give sulfide (*S<sub>p</sub>*)-**18** (84%). As in the cases of **2** and **12**, ferrocene derivative **18** could be selectively deprotonated adjacent to the bromide substituent and subsequent reaction with DMF gave aldehyde (*S<sub>p</sub>*)-**19** in 74% yield. Reduction with  $\text{LiAlH}_4$  resulted in alcohol (*S<sub>p</sub>*)-**20**, which on reaction with *n*-BuLi led to the desired 1,3-disubstituted ferrocene derivative



**Scheme 4** Synthesis of 1,3-disubstituted ferrocenes; reaction sequence 3. (a) LDA, THF,  $-78\text{ }^{\circ}\text{C}$  3 h;  $\text{F}_2\text{BrCCBrF}_2$ , THF,  $-78\text{ }^{\circ}\text{C}$  30 min, rt 19 h, 85%; (b) NaI (6 equiv),  $\text{Me}_3\text{SiCl}$  (12 equiv),  $\text{CH}_3\text{CN}$ , rt 18 h, 84%; (c) Li-TMP, THF,  $-78\text{ }^{\circ}\text{C}$  30 min,  $-30\text{ }^{\circ}\text{C}$  3 h; DMF,  $0\text{ }^{\circ}\text{C}$  1 h, 74%; (d)  $\text{LiAlH}_4$ , THF,  $0\text{ }^{\circ}\text{C}$  1.5 h, 83%; (e)  $-78\text{ }^{\circ}\text{C}$ , *n*-BuLi,  $0\text{ }^{\circ}\text{C}$  30 min,  $\text{H}_2\text{O}$ , 92%. Overall yield **16**  $\rightarrow$  **21**: 40%.

(*R<sub>p</sub>*)-**21** (92%). As recently reported for its racemate,<sup>5</sup> **21** can easily be functionalised and can therefore serve as a valuable starting material for a variety of chiral, non-racemic 1,3-disubstituted ferrocene derivatives. This approach should also be applicable to compound **20** or analogues that are accessible from **18** with different electrophiles.

In summary we have demonstrated that chiral non-racemic 1- $\text{R}^1$ ,2- $\text{R}^c$ ,3- $\text{R}^2$ -trisubstituted ferrocenes can be synthesised in two steps from monosubstituted ferrocenes  $\text{Fc-R}^1$  with both steps involving *ortho*-deprotonations. Particularly combinations of stereoselectively *ortho*-directing groups  $\text{R}^1$  with bromide as the central substituent gave products with very high selectivity and in preparatively useful yields. Since bromide can easily be removed from 1- $\text{R}^1$ ,2-Br,3- $\text{R}^2$ -trisubstituted ferrocenes, chiral non-racemic 1- $\text{R}^1$ ,3- $\text{R}^2$ -disubstituted ferrocenes become accessible *via* this route. We assume that our method can be further extended with respect to both the *ortho*-directing groups  $\text{R}^1$  and the electrophiles used in order to introduce substituent  $\text{R}^2$ . Furthermore, functional group variations of  $\text{R}^1$  and  $\text{R}^2$  as well as of bromide will make easily available a variety of 1,2,3-tri- and 1,3-disubstituted ferrocenes for new applications.

The authors thank Solvias AG for a donation of Ugi's amine and the undergraduate students Martin Fritzenwanker, Christian Kowol, Katrin Prantz, Michael Reithofer and Raffael Schuecker for their enthusiastic help in synthesising a variety of ferrocene derivatives.

## Notes and references

† Typical procedure for the *ortho*-deprotonation of (*R,S<sub>p</sub>*)-**2**: The reaction was carried out under an argon atmosphere using standard vacuum line and Schlenk techniques. To a cooled ( $-78\text{ }^{\circ}\text{C}$ ) degassed solution of (*R,S<sub>p</sub>*)-**2** (500 mg, 1.488 mmol) in THF (5 mL) was added dropwise a solution of Li-TMP in THF (0.7 M, 4.25 mL, 2.976 mmol). The reaction mixture was stirred for 30 min at  $-78\text{ }^{\circ}\text{C}$  followed by 3 h at  $-30\text{ }^{\circ}\text{C}$ . The reaction temperature was lowered to  $-78\text{ }^{\circ}\text{C}$  and dimethylformamide (350  $\mu\text{L}$ , 4.516 mmol) was added. The temperature was raised to  $0\text{ }^{\circ}\text{C}$  and stirring continued for 16 h at this temperature. The reaction was quenched with saturated aqueous  $\text{Na}_2\text{CO}_3$  (15 mL) and diethyl ether was added. The phases were separated and the aqueous phase was extracted 3 times with

diethyl ether. The combined organic phases were washed with brine, dried (MgSO<sub>4</sub>) and the solvents removed under reduced pressure. The residue was purified by column chromatography on alumina. A mixture of petroleum ether (boiling range 69–72 °C), ethyl acetate and triethylamine (30 : 10 : 1) was used as the eluent to give product (*R,R*<sub>p</sub>)-**3** as a red oil (442 mg, 82%). Selected characterisation data. (*R,R*<sub>p</sub>)-**3**: δ<sub>H</sub>(400.1 MHz; CDCl<sub>3</sub>; CHCl<sub>3</sub>; ppm) 1.47 (3 H, d, *J* 6.9, CHCH<sub>3</sub>), 2.17 (6 H, s, N(CH<sub>3</sub>)<sub>2</sub>), 3.87 (1 H, q, *J* 6.9, CHCH<sub>3</sub>), 4.25 (5 H, s, Cp'), 4.61 (1 H, d, *J* 2.8, Cp-H4), 4.90 (1 H, d, *J* 2.8, Cp-H3), 10.22 (1 H, s, CHO); δ<sub>C</sub>(100.6 MHz; CDCl<sub>3</sub>; CDCl<sub>3</sub>; ppm) 15.81 (CH<sub>3</sub>), 41.04 (N(CH<sub>3</sub>)<sub>2</sub>), 55.65 (CH), 65.63 (Cp-C3), 69.59 (Cp-C4), 72.84 (Cp'), 75.29, 92.94 (2 Cp-C<sub>q</sub>), 193.94 (CHO), 1 Cp-C<sub>q</sub> not observed; *m/z* (EI, 60 °C) 362.9928 (M<sup>+</sup>, 30%); C<sub>15</sub>H<sub>18</sub>BrFeNO requires 362.9923), 321/319 (6), 268 (28), 239 (54), 212 (16); [α]<sub>D</sub><sup>20</sup> –720 (589 nm), –806 (578), –1334 (546) (*c* 0.128 in CHCl<sub>3</sub>). (*R,S*<sub>p</sub>)-**5**: yellow powder; mp 121–123 °C; δ<sub>H</sub>(400.1 MHz; CDCl<sub>3</sub>; CHCl<sub>3</sub>; ppm) 1.42 (3 H, d, *J* 6.9, CHCH<sub>3</sub>), 1.71 (1 H, br s, OH), 2.09 (6 H, s, N(CH<sub>3</sub>)<sub>2</sub>), 3.57 (1 H, q, *J* 6.9, CHCH<sub>3</sub>), 4.12 (1 H, m, Cp-H4), 4.12 (5 H, s, Cp'), 4.21 (1 H, m, Cp-H5), 4.25 (1 H, t, *J* 1.4, Cp-H2), 4.33 (2 H, s, CH<sub>2</sub>OH); δ<sub>C</sub>(100.6 MHz; CDCl<sub>3</sub>; CDCl<sub>3</sub>; ppm) 15.55 (CHCH<sub>3</sub>), 40.62 (N(CH<sub>3</sub>)<sub>2</sub>), 58.54 (CHCH<sub>3</sub>), 60.88 (CH<sub>2</sub>OH), 66.96, 66.99 (Cp-C4, Cp-C5), 69.00 (Cp'), 69.12 (Cp-C2), 87.75, 87.89 (2 Cp-C<sub>q</sub>); *m/z* (EI, 70 °C) 287.0980 (M<sup>+</sup>, 81%); C<sub>15</sub>H<sub>21</sub>FeNO requires 287.0973), 272 (25), 243 (90), 225 (27), 134 (100). [α]<sub>D</sub><sup>20</sup> –1.2 (589 nm), –1.6 (578), –7.9 (546) (*c* 0.674 in CHCl<sub>3</sub>). (*S*<sub>p</sub>)-**15**: yellow powder; mp 55–59 °C; δ<sub>H</sub>(400.1 MHz; CDCl<sub>3</sub>; CHCl<sub>3</sub>; ppm) 0.08 [6 H, s, 2 Si(CH<sub>3</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>], 0.93 [9 H, s, Si(CH<sub>3</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>], 1.49 (1 H, t, *J* 5.9, OH), 4.15 (5 H, s, Cp'), 4.19 (1 H, dd, *J* 2.0 and 1.3, Cp-H4), 4.22 (1 H, dd, *J* 2.0 and 1.3, Cp-H5), 4.29 (2 H, d, *J* 5.9, CH<sub>2</sub>OH), 4.30 (1 H, t, *J* 1.3, Cp-H2), 4.41 (2 H, s, CH<sub>2</sub>OTBDMS); δ<sub>C</sub>(100.6 MHz; CDCl<sub>3</sub>; CDCl<sub>3</sub>; ppm) –5.16 (2C Si(CH<sub>3</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>), 18.37 [C<sub>q</sub>, Si(CH<sub>3</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>], 25.97 [3 C Si(CH<sub>3</sub>)<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>], 60.75 (CH<sub>2</sub>OH), 61.16 (CH<sub>2</sub>OTBDMS), 67.52 (Cp-C4), 67.73 (Cp-C2), 68.03 (Cp-C5), 68.82 (Cp'), 88.43, 88.46 (2 Cp-C<sub>q</sub>); *m/z* (EI, 80 °C) 360.1197 (M<sup>+</sup>, 100%); C<sub>18</sub>H<sub>28</sub>FeO<sub>2</sub>Si requires 360.1208), 285 (3), 229 (19), 195 (20), 91 (49), 75 (28). [α]<sub>D</sub><sup>20</sup> –6.9 (589 nm), –6.5 (578), –9.1 (546) (*c* 0.583 in CHCl<sub>3</sub>). (*R*<sub>p</sub>)-**21**: yellow powder; mp 62–68 °C; δ<sub>H</sub>(400.1 MHz; CDCl<sub>3</sub>; CHCl<sub>3</sub>; ppm) 1.57 (1 H, t, *J* 5.8, OH), 2.27 (3 H, s, CH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>), 4.27 (5 H, s, Cp'), 4.34 (2 H, d, *J* 5.8, CH<sub>2</sub>OH), 4.39 (1 H, dd, *J* 2.4 and 1.5, Cp-H4), 4.41 (1 H, dd, *J* 2.4 and 1.5, Cp-H5), 4.48 (1 H, t, *J* 1.5, Cp-H2), 6.98–7.02 (2 H, m, C<sub>6</sub>H<sub>4</sub>-H<sub>ortho</sub>), 7.02–7.06 (2 H, m, C<sub>6</sub>H<sub>4</sub>-H<sub>meta</sub>); δ<sub>C</sub>(100.6 MHz; CDCl<sub>3</sub>; CDCl<sub>3</sub>; ppm) 20.88 (CH<sub>3</sub>C<sub>6</sub>H<sub>4</sub>), 60.51 (CH<sub>2</sub>), 69.44 (Cp-C4), 69.99 (Cp'), 74.26 (Cp-C2), 74.83 (Cp-C5), 77.36, 90.05 (2 C, Cp-C<sub>q</sub>), 126.94 (2 C, C<sub>6</sub>H<sub>4</sub>-C<sub>meta</sub>), 129.43 (2 C, C<sub>6</sub>H<sub>4</sub>-C<sub>ortho</sub>), 135.19, 136.36 (2 C, C<sub>6</sub>H<sub>4</sub>-C<sub>q</sub>); *m/z* (EI, 100 °C) 338.0424 (M<sup>+</sup>, 100%); C<sub>18</sub>H<sub>18</sub>FeOS requires 338.0428), 200 (85), 185 (37), 167 (15), 138 (11), 121 (19); [α]<sub>D</sub><sup>20</sup> –43.3 (589 nm), –44.1 (578), –43.7 (546) (*c* 0.513 in CHCl<sub>3</sub>).

- P. Barbaro, C. Bianchini, G. Giambastiani and S. L. Parisel, *Coord. Chem. Rev.*, 2004, **248**, 2131; R. C. J. Atkinson, V. C. Gibson and N. J. Long, *Chem. Soc. Rev.*, 2004, **33**, 313; *Catalytic Asymmetric Synthesis*, ed. I. Ojima, Wiley-VCH, Weinheim, 2000.
- T. J. Colacot, *Chem. Rev.*, 2003, **103**, 3101; *Ferrocenes: Homogeneous Catalysis, Organic Synthesis, Materials Science*, ed. A. Togni and T. Hayashi, VCH, Weinheim, 1995.
- N. D'Antona, D. Lambusta, R. Morrone, G. Nicolosi and F. Secundo, *Tetrahedron: Asymmetry*, 2004, **15**, 3835; T. Chuard, S. J. Cowling, M. Fernandez-Ciurleo, I. Jauslin, J. W. Goodby and R. Deschenaux, *Chem. Commun.*, 2000, 2109.
- For achiral ferrocene-based pincer ligands see: A. A. Koridze, S. A. Kuklin, A. M. Sheloumov, F. D. Dolgushin, V. Y. Lagunova, I. I. Petukhova, M. G. Ezernitskaya, A. S. Peregudov, P. V. Petrovskii, E. V. Vorontsov, M. Baya and R. Poli, *Organometallics*, 2004, **23**, 4585; A. A. Koridze, A. M. Sheloumov, S. A. Kuklin, V. Y. Lagunova, I. I. Petukhova, F. M. Dolgushin, M. G. Ezernitskaya, P. V. Petrovskii, A. A. Macharashvili and R. V. Chedia, *Russ. Chem. Bull.*, 2002, **51**, 1077; E. J. Farrington, E. Martinez Viviente, B. S. Williams, G. van Koten and J. M. Brown, *Chem. Commun.*, 2002, 308.
- C. Pichon, B. Odell and J. M. Brown, *Chem. Commun.*, 2004, 598.
- T. Izumi and T. Hino, *J. Chem. Technol. Biotechnol.*, 1992, **55**, 325.
- D. W. Slocum, R. L. Marchal and W. E. Jones, *Chem. Commun.*, 1974, 967.
- I. R. Butler, M. G. B. Drew, C. H. Greenwell, E. Lewis, M. Plath, S. Müssig and J. Szewczyk, *Inorg. Chem. Commun.*, 1999, **2**, 576.
- O. Riant, G. Argouarch, D. Guillauneux, O. Samuel and H. B. Kagan, *J. Org. Chem.*, 1998, **63**, 3511; F. Rebiere, O. Riant, L. Ricard and H. B. Kagan, *Angew. Chem.*, 1993, **105**, 644, *Angew. Chem., Int. Ed. Engl.*, 1993, **32**, 568.
- J. W. Han, N. Tokunaga and T. Hayashi, *Helv. Chim. Acta*, 2002, **85**, 3848.
- Analogous to: J. Cabou, J. Brocard and L. Pelinski, *Tetrahedron Lett.*, 2005, **46**, 1185.
- L. Xiao, R. Kitzler and W. Weissensteiner, *J. Org. Chem.*, 2001, **66**, 8912.
- For alternative syntheses of **10** and **11** see: T. E. Pickett, F. X. Roca and C. J. Richards, *J. Org. Chem.*, 2003, **68**, 2592; M. Widhalm, U. Nettekoven and K. Mereiter, *Tetrahedron: Asymmetry*, 1999, **10**, 4369; ref. 6.
- D. Guillauneux and H. B. Kagan, *J. Org. Chem.*, 1995, **60**, 2502.
- I. R. Butler and M. G. B. Drew, *Inorg. Chem. Commun.*, 1999, **2**, 234.